Ventyx Biosciences Inc (VTYX): VTYX—(-79%/AH)

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	826
Posts	119569
Boards Moderated	14
Alias Born	09/05/2002

DewDiligence

Re: DewDiligence post# 4

Monday, 11/06/2023 5:59:04 PM

Monday, November 06, 2023 5:59:04 PM

VTYX—(-79%/AH)—terminates VTX958 psoriasis and PsA programs following phase-2 readout:

https://finance.yahoo.com/news/ventyx-biosciences-announces-results-phase-210100036.html

Although the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support advancement of VTX958 in plaque psoriasis. Accordingly, we will terminate ongoing activities in the Phase 2 plaque psoriasis trial effective immediately. Based on these results, we have also elected to terminate the ongoing Phase 2 trial of VTX958 in psoriatic arthritis.

The ongoing Phase 2 trial of VTX958 in Crohn’s disease will continue to enroll and we intend to conduct an interim efficacy analysis in the first quarter of 2024.

VTX952 is a TYK2 inhibitor, the same drug class as BMY’s Sotyktu.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”